Long Branch, NJ, September 08, 2011 --(PR.com
)-- Francesco International Inc., a pharmaceutical think-tank and healthcare consultancy has just released a major pharmaceutical report via the Internet. “The Major Global Expansion of Rx-to-OTC Switch by 2016©” is a 100 page report asserting that selected prescription (Rx) drugs will gain over-the-counter (OTC) status in the near future. As a result, the quality of life for the consumer will be significantly enhanced as the use of new technology dramatically improves self-medication with these drugs and justifies their use without physician involvement.
This report addresses strategic and operational “enabled” over-the-counter (OTC-E™) issues that will help define, create and put into action the efforts that will result in accelerated growth of the global over-the-counter (OTC) market.
The combination of these drugs plus new enabling technology will create a group of nonprescription drugs that Francesco International refers to as OTC-E™ drugs. These OTC-E™ drugs have several distinct characteristics. Most important, this new group of drugs will be used primarily for chronic therapy treatment. Amongst others, therapy areas impacted will be hypertension, dermatology, lipid-lowering, osteoporosis, arthritis and incontinence. For example, drugs such as Lipitor will be used OTC by 2016 for lowering cholesterol to help prevent cardiovascular disease.
“This is a breakthrough report that focuses on the changing dynamics of Rx-to-OTC switch between now and 2016,” says Steven Francesco, the principal author of the report and CEO of Francesco International.
The report is for companies interested in exploring the promising opportunities of Rx-to-OTC switch that will surface in the next five years. In addition, it will identify key therapy and product areas for switches that can benefit from a combination of the drug plus the use of the exciting new technology.
According to Francesco, “The US healthcare system has been in an unsatisfactory gridlock for some years now with payers, providers, pharmaceutical companies, patients and consumers all somewhat frustrated. Finally, the major players are now starting to move and some of these new dynamics, especially the contribution of technology, are becoming apparent. If you can see what is starting to happen overall and then drill down with regard to Rx-to-OTC switch, you can see some very positive trends emerging. This report captures what is happening now and what is likely to happen over the next few years, especially the implications for Rx-to-OTC switch. The report recognizes that we are at the beginning of a process. There will be winners and losers as the dynamics change. This report is essential for those who want a guide for solid long-term growth coming from the global Rx-to-OTC space.”
This report has been highly anticipated in the industry and has already created enough buzz to ignite dual collaborations. Francesco International will be teaming up with leading global research firm ORC International to present the webinar “The Revival of Rx to OTC Switch: Improved Market Dynamics Fuel Expansion,” scheduled for Sept. 21, 2011 at 1 p.m. EST. Francesco International will also be presenting a second Webinar with the widely read pharmaceutical website Pharmalot, “The Major Growth of Rx-to-OTC Switch Category©: OTC-E™ Drugs will Lead the Way,” on Oct. 13, 2011 at 1 p.m. EST.
For more information on “The Major Expansion of the Rx-to-OTC Switch by 2016©” or Francesco International visit www.franint.com.
About Francesco International Inc.
Francesco International Inc. has been actively involved in pharmaceutical lifecycle management with a focus on Rx-to-OTC switch for nearly two decades, consulting for numerous pharmaceutical companies worldwide. The firm published the newsletter, “SWITCH,” as well as SWITCH Market Impact studies. It has its own proprietary planning model “Max the Molecule” for assessing opportunities. CEO Steven Francesco has authored over fifty articles and essays on the pharmaceutical industry and is a recognized expert on product life cycle issues. He has been on the board of several companies and is also the CEO of MMDerm LLC.